Projects awarded for the management of medical images in a Phase III study for non-small cell lung cancer and in a Phase II study for bladder cancer;
Signing of a new contract with an Asian biotech company to manage imaging in a Phase II study for breast cancer.
MEDIAN Technologies (ALMDT), a leading medical imaging solutions and service provider for image interpretation and management in oncology clinical trials, cancer screening programs and routine practice in oncology, announced today that it has been selected to provide imaging solutions and services for three new studies, sponsored by leading global pharmaceutical companies and an Asian biotechnology company. These new studies represent approximately € 1.4M in project awards [*] and € 180K in signed contracts, for a total of € 1.58M.
Two of these studies are sponsored by historical clients of MEDIAN Technologies, one of which will base its Go/No Go decision for a later clinical phase on MEDIAN’s implementation of an advanced imaging biomarker. The third study is sponsored by one of the Top 10 pharmaceutical companies, now a new client for MEDIAN.
Together, these studies will involve more than 280 clinical sites across the world. Studies will start over a period running from Q4 2014 to Q4 2015.
“Through these new project awards and this new contract, our list of historical customers becomes more solid, confirming the relevance of our imaging solutions and services for clinical trials. We are particularly pleased, in this regard, that one of our historical customers, with whom we had worked in the context of their phases I and II, has now entrusted us with the management of imaging data in their phase III, demonstrating their confidence and satisfaction.” said Fredrik Brag, CEO of MEDIAN Technologies. “Moreover, we are also proud to count among our new clients a member of the top 10 global pharmaceutical companies, which adds to our existing Top 10 clients” he added.
[*] A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.